NEXTURNBIOSCIENCE Statistics
Total Valuation
NEXTURNBIOSCIENCE has a market cap or net worth of KRW 40.71 billion. The enterprise value is 89.58 billion.
Market Cap | 40.71B |
Enterprise Value | 89.58B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
Earnings Date | Nov 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
NEXTURNBIOSCIENCE has 11.28 million shares outstanding. The number of shares has increased by 25.94% in one year.
Current Share Class | n/a |
Shares Outstanding | 11.28M |
Shares Change (YoY) | +25.94% |
Shares Change (QoQ) | +14.87% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 3.38% |
Float | 8.59M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.98 |
PB Ratio | 0.29 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -3.64 |
EV / Sales | 2.47 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -16.96 |
Financial Position
The company has a current ratio of 1.93, with a Debt / Equity ratio of 0.60.
Current Ratio | 1.93 |
Quick Ratio | 1.42 |
Debt / Equity | 0.60 |
Debt / EBITDA | 100.95 |
Debt / FCF | -16.10 |
Interest Coverage | -0.22 |
Financial Efficiency
Return on equity (ROE) is -16.36% and return on invested capital (ROIC) is -0.31%.
Return on Equity (ROE) | -16.36% |
Return on Assets (ROA) | -0.28% |
Return on Capital (ROIC) | -0.31% |
Revenue Per Employee | 624.47M |
Profits Per Employee | -424.37M |
Employee Count | 58 |
Asset Turnover | 0.15 |
Inventory Turnover | 3.47 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.96% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -31.96% |
50-Day Moving Average | 3,545.90 |
200-Day Moving Average | 3,693.63 |
Relative Strength Index (RSI) | 44.83 |
Average Volume (20 Days) | 2,498,300 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NEXTURNBIOSCIENCE had revenue of KRW 36.22 billion and -24.61 billion in losses. Loss per share was -2,585.55.
Revenue | 36.22B |
Gross Profit | 7.93B |
Operating Income | -1.12B |
Pretax Income | -26.57B |
Net Income | -24.61B |
EBITDA | 842.33M |
EBIT | -1.12B |
Loss Per Share | -2,585.55 |
Balance Sheet
The company has 36.16 billion in cash and 85.03 billion in debt, giving a net cash position of -48.88 billion or -4,334.58 per share.
Cash & Cash Equivalents | 36.16B |
Total Debt | 85.03B |
Net Cash | -48.88B |
Net Cash Per Share | -4,334.58 |
Equity (Book Value) | 142.74B |
Book Value Per Share | 12,658.93 |
Working Capital | 26.00B |
Cash Flow
In the last 12 months, operating cash flow was -4.31 billion and capital expenditures -969.94 million, giving a free cash flow of -5.28 billion.
Operating Cash Flow | -4.31B |
Capital Expenditures | -969.94M |
Free Cash Flow | -5.28B |
FCF Per Share | -468.33 |
Margins
Gross margin is 21.88%, with operating and profit margins of -3.08% and -67.96%.
Gross Margin | 21.88% |
Operating Margin | -3.08% |
Pretax Margin | -73.36% |
Profit Margin | -67.96% |
EBITDA Margin | 2.33% |
EBIT Margin | -3.08% |
FCF Margin | -14.58% |
Dividends & Yields
NEXTURNBIOSCIENCE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -25.94% |
Shareholder Yield | -25.94% |
Earnings Yield | -71.62% |
FCF Yield | -12.97% |
Stock Splits
The last stock split was on April 12, 2023. It was a reverse split with a ratio of 0.2.
Last Split Date | Apr 12, 2023 |
Split Type | Reverse |
Split Ratio | 0.2 |
Scores
NEXTURNBIOSCIENCE has an Altman Z-Score of 0.84. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.84 |
Piotroski F-Score | n/a |